MPN patients harbor recurrent truncating mutations in transcription factor NF-E2

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• The molecular basis of myeloproliferative neoplasms (MPNs) is not fully understood.
• Previous research identified NF-E2 transcription factor overexpression in MPN patients.
• Elevated NF-E2 levels in mice induced MPN phenotypes and leukemic transformation.

Purpose of the Study:

• To investigate the role of acquired mutations in the NF-E2 gene in MPN pathogenesis.
• To determine the functional consequences of these NF-E2 mutations.
• To elucidate the contribution of enhanced NF-E2 activity to MPN development.

Main Methods:

• Analysis of NF-E2 gene in MPN patient samples for insertion and deletion mutations.
• Generation of a murine model expressing truncated NF-E2 proteins.
• Assessment of erythrocytosis, thrombocytosis, and cellular proliferation in the murine model.

Main Results:

• Acquired insertion and deletion mutations in the NF-E2 gene were identified in MPN patients.
• Truncated NF-E2 proteins enhanced wild-type NF-E2 function.
• Mutant NF-E2 cells exhibited a proliferative advantage and clonal dominance in vivo.
• The murine model developed erythrocytosis and thrombocytosis.

Conclusions:

• Acquired mutations leading to enhanced NF-E2 activity are implicated in MPN pathophysiology.
• Truncated NF-E2 proteins contribute to the proliferative advantage of MPN cells.
• Increased NF-E2 activity is a key driver in the development of MPNs.